21 September 2022 | News
Developing and commercializing Vaborem in China
Image credit: shutterstock
A. Menarini Asia-Pacific Holdings, part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) have entered into an exclusive licensing agreement to develop and commercialize Vaborem (meropenem and vaborbactam) in the People's Republic of China (China).
This initiative serves to expand options to address the public health threat of antimicrobial resistant (AMR) infections, specifically carbapenem-resistant Enterobacterales (CRE). Currently, Vaborem is being used to treat patients in the European Union for a variety of indications including complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP) and is approved in the United States of America to treat cUTI.
Menarini acquired the exclusive rights from Melinta in 2018 to market and sell Vaborem (meropenem and vaborbactam) in 68 countries in Europe, the Commonwealth of Independent States and Asia-Pacific.